Table 1.
Temperature sensitive polymeric nanoparticles fabricated with polymers exhibiting lower critical solution temperature (LCST).
| Copolymer | Drug | Size (nm) | LCST | Release Rate | Ref |
|---|---|---|---|---|---|
| PNIPAAm-PBMA poly(N-isopropylacrylamide-b-butylmethacrylate) |
Doxorubicin | 338 ± 23 | 32.5 °C | 57% after 5 h at 37 °C 80% after 5 h at 40 °C |
[130] |
|
P-(NIPAAm-co-DMAAm)-b-P-(d,l-lactide) poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(d,l-lactide) |
Doxorubicin | 69.2 | 40 °C | 2.5% after 4 days at 37 °C 11% after 4 days at 42.5 °C |
[139] |
| PNIPAAm-b-PMMA poly(N-isopropylacrylamide-b-methyl methacrylate) |
Prednisone acetate | 190 | 33 °C | 22.5% after 5 h at 27 °C 37 °C na 50% after 5 h at 40 °C |
[131] |
|
P-(NIPAAm-co-AAm)-b-PDLLA poly(N-isopropylacrylamide-co-acrylamide)-b-poly(d,l-lactide) |
Docetaxel | 80 | 40 °C | 30% after 10 h at 37 °C 36% after 10 h at 43 °C |
[140] |
|
P-(NIPAm-co-AAm) poly(N-isopropylacrylamide-co-acrylamide) |
Docetaxel | 50 | 40 °C | 80% after 50 h at 37 °C 40% after 50 h at 43 °C |
[126] |
|
P-(NIPAAm-co-AAm)-b-PBMA poly(N-isopropylacrylamide-co-acrylamide)-b-poly(n-butyl methacrylate) |
Methotrexate | 175 ± 15 | 40 °C | 21% after 5 h at 37 °C 53% after 5 h at 42 °C |
[141] |
|
P-(NIPAAm-co-NHMAAm)-b-PCL P-(N,N-isopropylacrylamide-co-N-hydroxymethylacrylamide)-b-caprolactone |
Doxorubicin | 97.2 ± 20.4 | 38 °C | 35% after 25 h at 38 °C Na at 37 57% after 25 h at 43 °C |
[128] |
| PNI-U-DPy poly(N-isopropylacrylamide) containing pendant U-DPy |
Doxorubicin | 164 | 34 °C | 63% 2.5 h 37 | [133] |
| Cy-functionalized supramolecular polymer, Cy-PPG | Doxorubicin | 76 | 45 °C | 5% after 2.5 h at 25 °C 37 °C na 85% after 2.5 h at 40 °C |
[121] |
| NIPAM-co-AAc poly(NIPAM-co-acrylic acid) |
Doxorubicin retinoic acid |
400 at 25 °C 100 at 37 °C |
37.2 °C | 40% after 4 h at 37 °C 80% after 48 h at 37 °C |
[127] |
| Pentaerythritol polycaprolactone-b-poly(N-isopropylacrylamide)-folic acid (four star-arm PE-PCL-b-PNIPAM-FA) |
Doxorubicin | 85 | 31 °C | 5% after 5 h at 37 °C 45% after 5 h at 40 °C |
[142] |
| Pentaerythritol polycaprolactone-b-poly(N-vinylcaprolactam)-Folic acid (four star-arm PE-PCL-b-PNVCL-FA) |
Doxorubicin | 185 | 39 °C | 5% after 5 h at 37 °C 50% after 5 h at 40 °C |
[142] |
| (cb-P-(HEMA-g-P-(NIPAAm-st-HEAAm))) cyclic brush poly(2-hydroxyethyl methacrylate-gpoly(N-isopropylacrylamide-st-N-hydroxyethylacrylamide)) (cb-P-(HEMA-g-P-(NIPAAm-st-HEAAm))) |
Doxorubicin | 28 | 38 °C | 28% after 40 h at 25 °C 32% after 40 h at 37 °C 52.5% after 40 h at 40 °C |
[120] |